Adaptimmune has patented a method to predict potential cross-reactivity of binding peptides in vivo. The method involves identifying binding motifs in target peptides and testing for off-target peptides to prevent unwanted side effects. This innovation aims to improve treatment efficacy and safety in human subjects. GlobalData’s report on Adaptimmune gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Adaptimmune Ltd - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Adaptimmune, was a key innovation area identified from patents.

Method for predicting and preventing cross reactivity in peptide administration

Source: United States Patent and Trademark Office (USPTO). Credit: Adaptimmune Ltd

A recently granted patent (Publication Number: US11929151B2) outlines a method for treating diseases in human subjects by administering a binding peptide selected to bind to a target peptide presented by a human leukocyte antigen (HLA) while preventing unwanted side effects. The method involves identifying binding motifs in the target peptide, searching for off-target peptides with similar motifs, testing for potential cross-reactivity, and selecting a binding peptide predicted to not cause unwanted side effects in vivo. This selection process includes creating mutant peptides to determine tolerated and non-tolerated amino acids within the binding motif.

The patent further specifies that the HLA can be of class I or class II, and the binding peptide can be a T cell receptor (TCR), chimeric antibody receptor (CAR), monoclonal antibody, or bispecific immunotherapeutic agent. In particular, the method highlights the use of a soluble TCR, potentially fused with an immune effector domain such as anti-CD3 antibody fragment, for treating diseases like cancer. The alternative amino acids considered in the process are alanine or glycine, and the search for off-target peptides includes those of human origin or commonly present in humans, ensuring specificity and safety in the treatment process.

To know more about GlobalData’s detailed insights on Adaptimmune, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies